5 Key Takeaways

• 1

  Clinical trials face significant delays due to operational bottlenecks, with average cycle times increasing by 14 months from 2020 to 2024.

• 2

  Over 80% of AI investments in pharmaceutical R&D since 2015 have focused on early discovery, neglecting clinical development.

• 3

  CRAs are overwhelmed by manual tasks and data management, leading to extended periods of inactivity known as 'white space'.

• 4

  Agentic AI has the potential to automate administrative tasks, allowing CRAs to focus on higher-value strategic responsibilities.

• 5

  AI agents can analyze operational data to identify patterns, improving efficiency and tailoring strategies for clinical trials.